Artificial Intelligence (AI) For De Novo Drug Design Market Report 2026

Artificial Intelligence (AI) For De Novo Drug Design Market Overview

• Artificial Intelligence (AI) For De Novo Drug Design market size has reached to $1.9 billion in 2025 • Expected to grow to $8.07 billion in 2030 at a compound annual growth rate (CAGR) of 33.7% • Growth Driver: Increasing Prevalence Of Complex Diseases Driving The Market Growth Due To Rising Chronic Health Conditions And Multifactorial Disease Burden • Market Trend: Innovations In Artificial Intelligence (AI)-Native Platforms Accelerate De Novo Drug Design And Molecular Optimization • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Artificial Intelligence (AI) For De Novo Drug Design Market?

Artificial intelligence (AI) for de novo drug design is the use of machine learning and computational algorithms to create novel molecular structures with targeted biological properties. It applies pattern recognition, predictive modeling, and optimization techniques to efficiently navigate vast chemical spaces. AI-driven methods accelerate the discovery of potential drug candidates while minimizing dependence on traditional trial-and-error approaches. The main components of artificial intelligence (AI) for de novo drug design include software and services. Software refers to platforms that leverage AI algorithms to accelerate drug discovery, including target identification and lead compound optimization. The therapeutic areas include oncology, neurological disorders, infectious diseases, cardiovascular diseases, rare diseases, metabolic disorders, and other therapeutic areas and are deployed through on-premises and cloud-based solutions. They find application in target identification, lead compound generation, molecular property prediction, absorption, distribution, metabolism, excretion, and toxicity (ADMET) prediction, and others, serving end users including pharmaceutical companies, biotechnology companies, academic and research institutes, contract research organizations, and other end users.

What Is The Artificial Intelligence (AI) For De Novo Drug Design Market Growth Forecast?

The artificial intelligence (AI) for de novo drug design market size is expected to see exponential growth in the next few years. It will grow to $8.07 billion in 2030 at a compound annual growth rate (CAGR) of 33.7%. The growth in the forecast period can be attributed to growing adoption of ai-driven lead compound generation, increasing use of admet prediction models, rising integration of cloud and on-premises deployment, expansion of model development and data annotation services, growing collaboration between pharmaceutical and biotech companies. Major trends in the forecast period include increasing adoption of cloud-based ai platforms, rising demand for deep learning-based drug design software, growing integration of workflow automation in drug discovery, expansion of molecular property prediction tools, rising focus on targeted therapeutic area applications.

Global Artificial Intelligence (AI) For De Novo Drug Design Market Segmentation

1) By Component: Software, Services 2) By Therapeutic Area: Oncology, Neurological Disorders, Infectious Diseases, Cardiovascular Diseases, Rare Diseases, Metabolic Disorders, Other Therapeutic Areas 3) By Deployment Mode: On-Premises, Cloud-Based 4) By Application: Target Identification, Lead Compound Generation, Molecular Property Prediction, Absorption, Distribution, Metabolism, Excretion, And Toxicity (ADMET Prediction), Other Applications 5) By End User: Pharmaceutical Companies, Biotechnology Companies, Academic And Research Institutes, Contract Research Organizations, Other End Users Subsegments: 1) By Software: Cloud Based Software, On Premise Software, Machine Learning Software, Deep Learning Software, Molecular Modeling Software, Data Analytics Software, Workflow Automation Software 2) By Services: Consulting Services, Integration Services, Maintenance And Support Services, Training And Education Services, Managed Services, Data Annotation Services, Model Development Services

What Is The Driver Of The Artificial Intelligence (AI) For De Novo Drug Design Market?

The increasing prevalence of complex diseases is expected to propel the growth of artificial intelligence (AI) for the de novo drug design market going forward. Complex diseases refer to health conditions that are caused by a combination of genetic, environmental, and lifestyle factors, often involving multiple body systems and requiring advanced or long-term medical management. The prevalence of complex diseases is rising due to unhealthy lifestyle habits, which increase the risk of chronic conditions such as diabetes, cardiovascular diseases, and certain cancers. Artificial intelligence (AI) for de novo drug design enhances the discovery of novel therapies by analyzing complex biological data and predicting effective drug candidates, thereby addressing the challenges posed by multifactorial and chronic complex diseases. For instance, in February 2024, according to the World Health Organization, a Switzerland-based international organization, more than 35 million new cancer cases are projected by 2050, representing a 77% rise compared to the estimated 20 million cases reported in 2022. Therefore, the increasing prevalence of complex diseases is driving the growth of the artificial intelligence (AI) for de novo drug design industry.

Key Players In The Global Artificial Intelligence (AI) For De Novo Drug Design Market

Major companies operating in the artificial intelligence (AI) for de novo drug design market are Schrödinger Inc., XtalPi Holdings Ltd., Owkin Inc., Insilico Medicine Inc., Recursion Pharmaceuticals Inc., Deep Genomics Inc., Iktos SA, Atomwise Inc., Terray Therapeutics Inc., Evogene Ltd., Genesis Therapeutics Inc., Insitro Inc., Verge Genomics Inc., DeepCure Inc., Cloud Pharmaceuticals Inc., Gero LLC, Chai Discovery Inc., Latent Labs Ltd., BioAge Labs Inc., Peptone Ltd., Generate Biomedicines Inc.

Global Artificial Intelligence (AI) For De Novo Drug Design Market Trends and Insights

Major companies operating in the artificial intelligence (AI) for de novo drug design market are focusing on developing innovative solutions, such as artificial intelligence (AI)-native drug discovery platforms, to accelerate the design and optimization of novel small molecules. Artificial intelligence (AI)-native drug discovery platforms are integrated systems that use AI models to generate, predict, and select novel molecules from scratch, helping accelerate drug discovery by identifying promising compounds faster and more efficiently than traditional trial-and-error methods. For instance, in November 2025, Terray Therapeutics, a US-based biotechnology company, launched EMMI (Experimentation Meets Machine Intelligence), an AI-native drug discovery platform specifically built for de novo small molecule design. It integrates Terray’s proprietary ultra-miniaturized experimental hardware with a highly automated lab and the Chemistry-Oriented AI Transformer Interface, third generation (COATI3) chemistry foundation model, to generate millions of novel molecules, predict their potency, select the most promising candidates, and iteratively optimize them. The platform’s generative AI uses reinforcement learning to propose synthetically accessible molecules, while predictive AI models rapidly evaluate properties like potency, selectivity, solubility, metabolism, and clearance, and the selection AI optimizes which molecules to synthesize to reduce time and cost by up to threefold compared to industry standards. EMMI has applications across internal immunology programs as well as partnerships targeting previously unexplored chemical space, making it a transformative tool for de novo drug design.

What Are Latest Mergers And Acquisitions In The Artificial Intelligence (AI) For De Novo Drug Design Market?

In July 2023, BioNTech SE, a Germany-based biopharmaceutical technology company, acquired InstaDeep Ltd. for $549 million (€500 million). With this acquisition, BioNTech aimed to strengthen and expand its strategic capabilities in artificial intelligence-driven drug discovery and development, integrating advanced AI/ML technologies to accelerate the design of next-generation immunotherapies and vaccines. InstaDeep Ltd. is a UK-based technology company that specializes in providing advanced artificial intelligence and machine learning solutions that support the de novo drug design.

Regional Insights

North America was the largest region in the artificial intelligence (AI) for de novo drug design market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Artificial Intelligence (AI) For De Novo Drug Design Market?

The artificial intelligence (AI) for de novo drug design market consists of revenues earned by entities by providing services such as molecular design and generation, target identification and validation, lead optimization, predictive modeling and simulation, data analysis and integration, and virtual screening. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data And Analysis Are Included In The Artificial Intelligence (AI) For De Novo Drug Design Market Report 2026?

The artificial intelligence (ai) for de novo drug design market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the artificial intelligence (ai) for de novo drug design industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.